The mRNA expression of AIF and PARP-1 in HPV negative non-tumour epithelial cells and HPV-positive cervical cancer cells using the real-time PCR method was examined. An increased level of AIF and PARP-1 mRNA in cervical cancer cells in comparison to normal epithelial cells was demonstrated. These results suggest that changes in the mRNA expression level of AIF and PARP-1 might be involved in cervical cancer development. The analysis of these two factors may represent a new molecular tool for cervical cancer prevention in women with HPV persistent infection.
1. Cepeda V., Fuertes A.M., Castilla J., Alonso C., Quevedo C., Soto M., Perez J.M.: Poly (ADP-ribose) polymerase-l (PARP-1) inhibitors in cancer chemotherapy. Recent Pat Anticancer Drug Discov 2006, 1, 39-53.
2. Chalmers A.J.: The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009, 89, 23-40.
3. Daud I.I., Scott M.E.: Validation of reference genes in cervical cell samples from human papillomavirus- infected and -uninfected women for quantitative reverse transcription-PCR assays. Clin Vaccine Immunol 2008, 15, 1369-1373.
4. Delettre C., Yuste J.V., Moubarak R.S., Bras M., Robert N., Susin S.A.: Identification and characterization of AIFsh2, a mitochondrial apoptosis-inducing factor (AIF) isoform with NADH oxidase activity. J Biol Chem 2006, 281, 18507-18518.
5. Galluzzi L., Brenner C., Morselli E., Touat Z., Kroemer G.: Viral control of mitochondrial apoptosis. PLoS Pathog 2008, 4, 1-16.
6. Giansanti V., Dona F., Tillhon M., Scovassi A.I.: PARP inhibitors: new tools to protect from inflammation. Biochem Pharmacol 2010, 80, 1869-1877.
7. Hangen E., Blomgren K., Benit P., Kroemer G., Modjtahedi N.: Life with or without AIF. Trends Biochem Sci 2010, 35, 278-287.
8. Hong S.J., Dawson T.M., Dawson V.L.: Nuclear and mitochondrial conversation in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 2004, 25, 259-264.
9. Leal A.P., Rodriguez M.I., Oliver F.J.: Poly (ADP-ribose) polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin Transl Oncol 2008, 10, 318-323.
10. Lee W.J., Jeong E.G., Soung Y.H., Kim S.Y., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H.: Immunohistochemical analysis of apoptosis-inducing factor (AIF) expression in gastric carcinomas. Pathol Res Pract 2006, 202, 497-501.
11. Lehoux M., D'Abramo C., Archambault J.: Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics 2009, 12, 268- 280.
12. McLaughlin-Drubin M.E., Münger K.: Oncogenic activities of human papilomaviruses. Virus Res 2009, 143, 195-208.
13. Millan A., Huerta S.: Apoptosis-inducing factor and colon cancer. J Surg Res 2009, 151, 163-170.
14. Plummer R., Drew Y.: PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009, 12, 153-156.
15. Saelens X., Festjens N., Walle L.W., van Gurp M., van Loo G., Vandenabeele P.: Toxic proteins released from mitochondria in cell death. Oncogene 2004, 23, 2861- 2874.
16. Sandhu S.K., Yap T.A., de Bono J.S.: Poly (ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010, 46, 9-20.
17. Stambolsky M., Weisz L., Shats I., Klein Y., Goldfinger N., Oren M., Rotter V.: Regulation of AIF expression by p53, Cell Death Differ 2006, 13, 2140-2149.
18. Süsse S., Scholz C.J., Bürkle A., Wiesmüller L.: Poly (ADP-ribose) polymerase (PARP-1) and p53 independently function in regulating double-strand break repair in primate cells. Nucleic Acids Res 2004, 32, 669- 680.
19. Tommasino M., Accardi R., Caldeira S., Dong W., Malanchi I., Smet A., Zehbe 1.: The role of TP53 in cervical carcinogenesis. Hum Mutat 2003, 21, 307-312.
20. Urbano A., Lakshmanan U., Choo P.H., Kwan J.C., Ng P.Y., Guo K., Dhakshinamoorthy S., Porter A.: AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells. EMBO J 2005, 24, 2815-2826.